Human IL-6 knockout A549 cell lysate (ab275501)
Overview
-
Product name
Human IL-6 knockout A549 cell lysate
See all IL-6 kits -
Product overview
Knockout cell lysate achieved by CRISPR/Cas9.
Treatments:
Human IL-6 knockout A549 cell lysate - Brefeldin A (5 µg/ml, 6h)
Human wild-type A549 cell lysate - Brefeldin A (5 µg/ml, 6h)
Human IL-6 knockout A549 cell lysate - IL-1ß (20 ng/ml, 24h) and Brefeldin A (5 µg/ml, during the last 6h of IL-1ß treatment)
Human wild-type A549 cell lysate - IL-1ß (20 ng/ml, 24h) and Brefeldin A (5 µg/ml, during the last 6h of IL-1ß treatment) -
Parental Cell Line
A549 -
Organism
Human -
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 97 bp deletion in exon 3 -
Passage number
<20 -
Knockout validation
Sanger Sequencing, Western Blot (WB) -
Reconstitution notes
To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.*Usage of SDS sample buffer is not recommended with these lyophilized lysates.
-
Notes
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: After reconstitution, store the lysate at -80°C.
Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
See here for more information on knockout cell lysates.This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
-
Tested applications
Suitable for: WBmore details
Properties
-
Storage instructions
Store at -80°C. Please refer to protocols. -
Components 1 kit ab277306 - Human IL6 knockout A549 cell lysate - Brefeldin A treated (Lyophilized) 1 x 100µg ab277307 - Human IL6 knockout A549 cell lysate - IL-1 beta + Brefeldin A treated (Lyophilized) 1 x 100µg ab277309 - Human wild-type A549 cell lysate - IL-1 beta + Brefeldin A treated (Lyophilized) 1 x 100µg ab277308 - Human wild-type A549 cell lysate - Brefeldin A treated (Lyophilized) 1 x 100µg -
Research areas
-
Cell type
epithelial -
Disease
Carcinoma -
Gender
Male
Target
-
Function
Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoeitic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance. -
Involvement in disease
Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men. -
Sequence similarities
Belongs to the IL-6 superfamily. -
Post-translational
modificationsN- and O-glycosylated. -
Cellular localization
Secreted. - Information by UniProt
-
Alternative names
- Interleukin BSF 2
- B cell differentiation factor
- B cell stimulatory factor 2
see all
Associated products
-
Biochemicals
-
KO cell lines
-
Recombinant Protein
-
Related Products
- Brefeldin A, Inhibitor of ADP-ribosylation factor (ab120299)
- Anti-IL-6 antibody [EPR20653] (ab214429)
- Anti-IL-6 antibody [EPR21711] (ab233706)
- Anti-IL-6 antibody [EPR21711] - BSA and Azide free (ab233707)
- Anti-IL-6 antibody [EPR20653] - BSA and Azide free (ab245770)
- Anti-IL-6 antibody [EPR21711] - Low endotoxin, Azide free (ab246703)
Applications
Our Abpromise guarantee covers the use of ab275501 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | Use at an assay dependent concentration. Predicted molecular weight: 23 kDa. |
Images
-
Lane 1: Wild-type A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate 30 ug
Lane 2: Wild-type A549 IL-1β (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate 30 ug
Lane 3: IL-6 knockout A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate 30 ug
Lane 4: IL-6 knockout A549 IL-1β (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate 30 ug
Lanes 1 - 4: Merged signal (red and green). Green - ab233706 observed at 25 kDa, possible non-specific binding at 40 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab233706 was shown to react with IL-6 in wild-type A549 cells in western blot with loss of signal observed in IL-6 knockout cell line ab273751 (knockout cell lysate ab275501). Wild-type and IL-6 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab233706 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging. -
Lane 1: Wild-type A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate 30 ug
Lane 2: Wild-type A549 IL-1β (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate 30 ug
Lane 3: IL-6 knockout A549 Brefeldin A (ab120299)-treated (5ug/ml, 4h) cell lysate 30 ug
Lane 4: IL-6 knockout A549 IL-1β (ab259387) (20 ng/ml, 24h) and Brefeldin A (ab120299)-treated (5 ug/ml for the last 4h) cell lysate 30 ug
Lanes 1 - 4: Merged signal (red and green). Green - ab214429 observed at 25 kDa, possible non-specific binding at 35 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A] observed at 55kDa.
ab214429 was shown to react with IL-6 in wild-type A549 cells in western blot with loss of signal observed in IL-6 knockout cell line ab273751 (knockout cell lysate ab275501). Wild-type A549 and IL-6 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab214429 and ab7291 (Mouse anti-Alpha Tubulin [DM1A] overnight at 4°C at a 1 in 1000 Dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging. -
Allele-1: 97 bp deletion in exon 3.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (0)
ab275501 has not yet been referenced specifically in any publications.